- GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - - RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – - Recent Valuations for PRVs Remain Attractive (~$100 million/each) – Oct. 15, 2024 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the deve

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension Oct. 15, 2024 -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced the Last Patient

2024年10月15日，TRIANA Biomedicines宣布，公司与已与辉瑞达成战略合作和许可协议，以发现用于多个疾病领域（包括肿瘤学）的针对多个靶点的新型分子胶降解剂。 根据协议条款，TRIANA 将获得 4900 万美元的预付款，并有资格获得超过 15 亿美元的潜在未来里程碑付款以及分级版税。TRIANA 将负责发现和识别潜在药物；辉瑞拥有候选药物的独家选择权，并拥有进一步对其进行临床前和临床开发的独家许可。 TRIANA是一家生物技术公司，2022年，公司曾完成由RA Capital和Atlas Venture领投、辉瑞等跟投的1.1亿美元A轮融资。 公司专注于构建领先的分子胶发现平台；该平台内置了一款AI算法来识别可能与蛋白质相互作用有关的蛋白质表面特征，且在现有的蛋白质作用网络上进行验证、测试，通过算法可以预测哪些靶蛋白具有更大的亲和力，且最有可能和靶蛋白形成复合物的E3连接酶进行排序。 除此以外，TRIANA对分子胶的选择还引入了药物筛选五法则，即口服医药小分子化合物应该具有的化学特性，例如氢键不超过五个，分子量在500以下等；上述法则有益于提升药物的体内吸收率

- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients - -Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year-end - Oct. 15, 2024 -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad popu

近日，恒瑞医药重新向美国食品药品监督管理局（FDA）提交了卡瑞利珠单抗（Camrelizumab，中文商品名：艾瑞卡®）联合甲磺酸阿帕替尼（Rivoceranib，中文商品名：艾坦®）（“双艾”组合）用于不可切除或转移性肝细胞癌患者一线治疗的生物制品许可申请（BLA），并得到正式受理。 本次申报上市，是基于恒瑞医药推进开展的一项国际多中心III期临床研究（CARES-310研究）的积极结果。2023年7月，该研究期中数据重磅发表于《柳叶刀》主刊（The Lancet，IF：168.9），这是中国肿瘤领域学者主导的国际Ⅲ期临床研究首次问鼎《柳叶刀》主刊，实现了“零”的突破1。2024年美国临床肿瘤学会（ASCO）年会上，该研究报告了继续随访16个月后的最终分析（FA）的更新数据2，“双艾”组合一线治疗晚期肝癌具有显著的生存获益和可耐受的安全性，中位总生存期（mOS）达到23.8个月，患者生存获益再创新高。所有获批肝细胞癌一线治疗适应症的方案中，“双艾”方案成为迄今为止获得最长中位OS研究数据的治疗方案3-8。 根据GLOBOCAN 2022公布的数据，2022年全球新发肝癌病例约86

Oct. 14, 2024 -- GEn1E Lifesciences, a clinical-stage Phase 2 company, and a leading innovator in precision therapies for inflammatory and rare diseases, with a strong partnership with the University of Maryland, Baltimore (UMB), today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET). The study, titled First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator wit

Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, with prevalence approximately five times that of APDS Clinical trial being conducted at the National Institutes of Health (NIH) October 10, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the start of a

14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT Oct. 14, 2024 -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of br

Oct. 14, 2024 -- INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and autoimmune diseases. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the “NAYA” ticker. The combined company will continue to operate the revenue-generating fertility business as well as expand its focus to the development of first-in-c

今日，Jasper Therapeutics公布其进行中SPOTLIGHT临床1b/2a期研究的初步数据。分析显示，慢性诱发性荨麻疹（CIndU）患者在接受其在研药物briquilimab皮下注射后1周便观察到完全缓解（CR），且93%的患者在接受治疗后6周达成缓解。该公司已获得监管批准在SPOTLIGHT研究中招募患者接受更高剂量药物的治疗。Jasper Therapeutics预计将在2025年上半年公布SPOTLIGHT研究的全部数据。 荨麻疹，又称风疹块，是一种引起皮肤瘙痒和肿块的反应。慢性荨麻疹的特征是斑块持续时间超过六周，并常在数月甚至数年间反复出现。最初，这些斑块通常表现为瘙痒的小块，逐渐发展为大小不一的肿胀斑块，且会不定期出现和消失，给患者带来显著的不适，影响其睡眠及日常生活。许多患者会使用抗组胺药等药物来缓解瘙痒。慢性荨麻疹分为慢性自发性荨麻疹（CSU）和CIndU，后者是由特定诱因（如冷、热、运动、压力、阳光、振动、水等）引发的荨麻疹，以风团和/或血管性水肿为主要表现。根据诱因不同，CIndU可分为物理性和非物理性两大类。物理性荨麻疹包括最常见的症状性皮肤划痕症（